On June 17, 2026, a new publication involving tesamorelin appeared in the journal eNeurologicalSci. The paper is titled "The effect of growth hormone-releasing hormone on cognition and brain connectivity in adults with cognition ranging from normal to mild cognitive impairment." Tesamorelin is a growth hormone-releasing hormone analog with an approved regulatory status. The publication is indexed under PubMed ID 42382101 and can be accessed through the provided source link. This entry reflects the existence and title of the publication as recorded. No specific findings, outcomes, or conclusions from the study are included here. Readers interested in the details of the research should consult the full text through the journal or the PubMed listing directly. This brief does not characterize or summarize any results, efficacy signals, or safety observations from the study, as none were provided in the event data. For general background on tesamorelin, including its approved uses and regulatory context, readers can consult the compound overview.
Tesamorelin Study on Cognition, Brain Connectivity Published
Drafted by an automated content engine from FDA, PubChem, ClinicalTrials.gov, NIH DSLD, and Open Beauty Facts data.
See the full tesamorelin overview
Source: https://pubmed.ncbi.nlm.nih.gov/42382101/